Clinical
Trials Units Selected for Newly Restructured
HIV/AIDSResearch
Networks
(Continued)
The
HIV/AIDS networks and their CTUs will pursue an integrated research approach
to conducting clinical trials designed to address the highest priorities in
HIV/AIDS research, including
·
Developing a safe and effective HIV vaccine
·
Conducting research for new drug development designed to translate lab findings
into clinical applications
·
Optimizing clinical management of HIV/AIDS, including co-infections and other
HIV-related conditions
·
Developing microbicides to prevent HIV acquisition and transmission
·
Creating strategies to prevent mother-to-child HIV transmission
·
Developing new methods of HIV prevention
Each unit will be led by a principal investigator and include an administrative component, community advisory board and one or more clinical research sites--such as medical schools, academic health centers, hospitals or outpatient clinics--where studies will be conducted. A list of the principal investigators who will lead the CTUs and their affiliated clinical research sites can be accessed at (http://www3.niaid.nih.gov/about/organization/daids/Networks/daidsnetworkunits.htm).
The U.S.-based CTUs will be located in the following states and territories: Alabama, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Washington and Puerto Rico. Additional CTUs are expected in Louisiana and Washington, D.C.
The CTUs located outside of the United States are in the following countries: the Dominican Republic, Haiti, Jamaica, Peru, South Africa and Switzerland. Additional CTUs are anticipated in Brazil, China, France, India and Thailand.
The 145 clinical research sites where trials will be performed may be located in different states or countries than the CTUs to which they are affiliated. In addition to the CTU locations noted above, clinical research sites are also anticipated in Michigan, Oklahoma, Rhode Island and Virginia and internationally in Botswana, Malawi, Panama, Tanzania, Uganda, Vietnam, Zambia and Zimbabwe.
The selection process for the CTUs involved a rigorous and extensive scientific peer review of the CTUs’ proposed clinical programs and capabilities, including access to populations most affected or threatened by the HIV/AIDS epidemic, particularly women, children, adolescents and people of diverse ethnic or racial backgrounds.
Return to HOME